Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients

• Paul J. Hengeveld,
• Joyce Schilperoord-Vermeulen,
• P. Martijn Kolijn,
• Julie M. N. Dubois,
• Peter E. Westerweel,
• Sabina Kersting,
• Arnon P. Kater,
• Mark-David Levin,
• Anton W. Langerak

Affiliations

Paul J. Hengeveld

Department of Immunology, Laboratory of Medical Immunology, Erasmus MC, University Medical Centre Rotterdam

Joyce Schilperoord-Vermeulen

Department of Immunology, Laboratory of Medical Immunology, Erasmus MC, University Medical Centre Rotterdam

P. Martijn Kolijn

Department of Immunology, Laboratory of Medical Immunology, Erasmus MC, University Medical Centre Rotterdam

Julie M. N. Dubois

Department of Hematology, Cancer Care Center Amsterdam, Amsterdam University Medical Centers

Peter E. Westerweel

Department of Internal Medicine, Albert Schweitzer Hospital

Sabina Kersting

Department of Hematology, Haga Hospital

Arnon P. Kater

Department of Hematology, Cancer Care Center Amsterdam, Amsterdam University Medical Centers

Mark-David Levin

Department of Internal Medicine, Albert Schweitzer Hospital

Anton W. Langerak

Department of Immunology, Laboratory of Medical Immunology, Erasmus MC, University Medical Centre Rotterdam